Bzl-L-Leu-OMe*HCl

Bzl-L-Leu-OMe*HCl is an L-leucine methyl ester hydrochloride bearing a benzyl (Bzl) protecting group on the amino functionality, yielding a chiral amino acid ester intermediate with a stereogenic center at the alpha carbon. The structure combines a protected primary amine (as a benzyl carbamate/benzyl-type amino protection motif) with an esterified carboxyl group (methyl ester), both of which modulate nucleophilicity and coupling behavior during peptide assembly. The hydrochloride salt form enhances handling and can improve crystallinity for synthetic workflows while maintaining compatibility with standard amino acid derivative transformations. The leucine side chain isopropyl group provides hydrophobic character and supports incorporation into peptide sequences and peptidomimetic scaffolds, while the protected amine and ester group enable controlled deprotection and downstream conversion to coupling-ready carboxyl derivatives.

1. Peptide Synthesis

Bzl-L-Leu-OMe*HCl is used in peptide synthesis workflows where a protected L-leucine methyl ester serves as a building block for stepwise chain elongation. The benzyl-protected amino functionality supports peptide coupling by limiting side reactions from the free amine, while the methyl ester can be transformed into activated carboxyl forms (e.g., via ester-to-acid or ester-to-coupling derivative strategies) to enable amide bond formation. The L-configuration at the alpha carbon preserves stereochemical integrity during assembly, which is critical for producing stereochemically defined peptide analogs and for maintaining consistent conformational preferences. Downstream conversion to carboxyl-activated intermediates supports incorporation of hydrophobic leucine residues into protected peptide fragments for research-grade synthesis and manufacturing-scale peptide intermediate preparation.

2. Protected Amino Acid Chemistry

Bzl-L-Leu-OMe*HCl functions as a protected amino acid derivative for controlled protection/deprotection sequences and intermediate generation in synthetic organic chemistry. The presence of the benzyl-protected amine and the methyl ester provides orthogonality relative to other functional groups commonly present in amino acid derivatives, enabling selective transformations that can be aligned with multi-step peptide building routes. The hydrochloride salt form can facilitate handling of the amine-protected ester during reagent addition and purification steps, supporting reproducible conversion to coupling-ready species. The leucine side chain remains chemically stable under many standard manipulations, allowing the compound to serve as a chiral intermediate for fine chemical synthesis and for preparing downstream amino acid derivatives used in peptide chemistry.

3. Chiral Building Block Development

Bzl-L-Leu-OMe*HCl is suitable for chiral synthesis and stereodefined intermediate preparation where retention of the L-stereocenter is required for structure-function studies. The alpha-amino acid architecture with a protected amine and esterified carboxyl group provides a controlled platform for stereospecific derivatization, including conversion to acids, activated esters, or alternative carboxyl derivatives used in fragment coupling. The leucine isopropyl side chain contributes hydrophobicity that can influence conformational behavior in peptidomimetics and in backbone-modified scaffolds, making the stereochemically defined building block useful for generating libraries of stereopure analogs. The compound's chiral nature supports consistent downstream stereochemical outcomes in synthetic methodology development and in the preparation of amino acid-derived intermediates for industrial fine chemical manufacturing.

4. Pharmaceutical Intermediate Preparation

Bzl-L-Leu-OMe*HCl is employed as an amino acid ester intermediate in pharmaceutical manufacturing supply chains for producing protected peptide fragments and related peptidomimetic building blocks. The benzyl-protected amino group and methyl ester functionality align with common industrial strategies for assembling peptide-like structures while managing reactive functional groups during process chemistry. The hydrochloride salt form can be leveraged to improve material handling characteristics for scale-up workflows that require reproducible solid-state behavior of amino acid derivatives. Conversion of the ester and subsequent deprotection steps can yield coupling-ready leucine units that integrate into larger protected sequences, supporting downstream synthesis of research-grade and process-relevant intermediates used in specialty chemical production.

5. Peptidomimetics And SAR Studies

Bzl-L-Leu-OMe*HCl can be applied in peptidomimetic construction and structure-activity relationship studies where defined incorporation of a leucine residue is needed to probe hydrophobic and steric contributions. The protected amine enables controlled formation of amide linkages during scaffold assembly, while the ester group can be manipulated to generate carboxyl functionalities compatible with coupling or scaffold diversification. L-leucine stereochemistry supports the generation of stereochemically consistent analog series, which is important for comparing structure-activity relationship trends across analogs. Downstream derivatives derived from this chiral amino acid ester can serve as intermediates for creating backbone-modified compounds, enabling systematic SAR-oriented synthesis within biochemical research and applied medicinal chemistry programs.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. TMEM16F and dynamins control expansive plasma membrane reservoirs

3. High fat diet and GLP-1 drugs induce pancreatic injury in mice

4. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

5. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines